2-氨基-3,3-二甲基丁酸甲酯 | 3850-31-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-氨基-3,3-二甲基丁酸甲酯
• 英文名称: methyl tert-leucinate
• 英文别名: 2-amino-3,3-dimethyl-butyric acid methyl ester；2-Amino-3,3-dimethyl-buttersaeure-methylester；(S)-methyl 2-amino-3,3-dimethylbutanoate；tert-Butylamino-acetic acid methyl ester；methyl 2-amino-3,3-dimethylbutanoate；(R,S)-tert.-Leucin-methylester
• CAS: 3850-31-5
• 化学式: C₇H₁₅NO₂
• mdl: MFCD01315996
• 分子量: 145.202
• InChiKey: WCYLIGGIKNKWQX-UHFFFAOYSA-N

物化性质

• 沸点：
  163.1±13.0 °C(Predicted)
• 密度：
  0.957±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P210,P240,P241,P242,P243,P261,P264,P271,P280,P302+P352,P303+P361+P353,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P370+P378,P403+P233,P403+P235,P405,P501
• 危险品运输编号：
  1993
• 危险性描述：
  H225,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氨基-3,3-二甲基丁酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 三乙胺 作用下， 以 四氯化碳 、 二氯甲烷 为溶剂， 生成 Methyl 2-benzamido-2-bromo-3,3-dimethylbutanoate
  参考文献：
  名称：

  Design of Radical-Resistant Amino Acid Residues:  A Combined Theoretical and Experimental Investigation

  摘要：

  Ab initio calculations have been used to design radical-resistant amino acid residues. Optimized structures of free and protected amino acids and their corresponding alpha-carbon-centered radicals were determined with B3-LYP/6-31G(d). Single-point RMP2/6-31G(d) calculations on these structures were then used to obtain radical stabilization energies, to examine the effect of steric repulsion between the side chains and amide carbonyl groups on the stability of alpha-carbon-centered peptide radicals. Relative to glycine, the destabilization for alanine and valine residues was found to be approximately 9 and 18 kJ mol(-1), respectively, which correlates with the reactivity of analogous amino acid residues in peptides toward hydrogen atom abstraction in conventional free radical reactions. To design amino acid residues that would resist radical reactions, strategies by which the steric effects could be magnified were considered. This resulted in the identification of tert-leucine and 3,3,3-trifluoroalanine as suitable molecules. With these amino acid residues, the destabilization of the alpha-carbon-centered radicals relative to that of glycine is increased substantially to approximately 36 and 41 kJ mol(-1), respectively. The theoretical predictions have been supported by experimental observations: a tert-leucine derivative was shown to be very slow to react with N-bromosuccinimide, while the corresponding trifluoroalanine derivative was found to be inert.

  DOI：

  10.1021/ja029674v
• 作为产物：
  描述：

  3,3-二甲基-2-氧代丁酸甲酯 在 正丁基锂 、 三甲基氯硅烷 、 sodium cyanoborohydride 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 1.25h， 生成 2-氨基-3,3-二甲基丁酸甲酯
  参考文献：
  名称：

  α-（N-三甲基甲硅烷基）亚氨基酯的制备及其在α-氨基酯和2-烷氧基羰基咪唑-4（2 H）-ones合成中的应用

  摘要：

  α-酮酯与1,1,1,3,3,3-六甲基二硅氮杂环丙烷锂的反应以良好的收率得到了α-（N-三甲基甲硅烷基）亚氨基酯，通过还原剂将其还原为相应的α-氨基酯。作为NaBH 3 CN。α-（N-三甲基甲硅烷基）亚氨基酯用甲醇处理，通过中间α-亚氨基酯的二聚作用得到2-烷氧基羰基咪唑-4（2H）-酮。

  DOI：

  10.1039/p19890000279

文献信息

• Methods and compounds for inhibiting mrp1
  申请人：——

  公开号：US20030100576A1

  公开（公告）日：2003-05-29

  The present invention further relates to a method of inhibiting MRP1 in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I).

  本发明还涉及一种抑制哺乳动物中MRP1的方法，包括向需要的哺乳动物施用化合物(I)的有效量。
• [EN] ASPARAGINE DERIVATIVES AND METHODS OF USING SAME<br/>[FR] DÉRIVÉS D'ASPARAGINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SENDA BIOSCIENCES INC

  公开号：WO2021252640A1

  公开（公告）日：2021-12-16

  The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

  本公开涉及式（A）和（I）的化合物，其药学上可接受的盐，以及任何上述化合物的溶剂化合物，包括相同的药物组合物，制备相同的方法，用于制备相同的中间化合物，以及使用相同的方法治疗或预防疾病，特别是癌症，如结直肠癌。
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DES CANNABINOÏDES
  申请人：ARENA PHARM INC

  公开号：WO2012116279A1

  公开（公告）日：2012-08-30

  Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor.

  提供了一些在治疗疼痛方面有用的方法，包括给予化合物Ia的复方及其药物组合物，以调节大麻素CB2受体的活性。
• [EN] COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS<br/>[FR] ASSOCIATIONS D'INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015005901A1

  公开（公告）日：2015-01-15

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组合物，以及抑制NS5A蛋白功能的方法。
• SUBSTITUTED IMIDAZOHETEROCYCLES
  申请人：Beckett R. Paul

  公开号：US20080318935A1

  公开（公告）日：2008-12-25

  The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.

  本发明提供了具有式I结构的取代咪唑杂环化合物。还提供了式I化合物的药用可接受盐、酸盐、水合物、溶剂合物和立体异构体。这些化合物可用作大麻素受体调节剂，用于预防和治疗与大麻素受体相关的疾病和症状，如疼痛、炎症和瘙痒。